Rade Tomic is a Respiratory physician affiliated with University of Chicago. OpenAlex indexes 788 publications with 3,067 citations (h-index 21); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
- DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies
Sponsor: Northwestern University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AmgenProgram year20252 paymentsResearch$6,151
- United Therapeutics CorporationProgram year20251 payment$81
- KAMADA LTD.Program year20251 payment$16
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
33.5%Macrolide Antimicrobial15.2%Azithromycin100%Part D≥64 patientsShort-acting sulfonamides10.5%Sulfamethoxazole-Trimethoprim100%Part D≥52 patients+ 4 more classes in this area
Metabolism & gastrointestinal
23.9%Proton pump inhibitor10.5%Pantoprazole Sodium52%Omeprazole38%Lansoprazole9%Part D<11 patientsCorticosteroid8.6%Prednisone100%Part D≥55 patients+ 3 more classes in this area
Cardiovascular
13.9%Statin4.7%Rosuvastatin Calcium74%Atorvastatin Calcium26%Part D<11 patientsBeta blocker3.8%Metoprolol Tartrate45%Carvedilol37%Metoprolol Succinate18%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Use of letermovir for cytomegalovirus primary prophylaxis in lung transplant recipients
Transplant Infectious Disease
2024 - Respiratory‐swallow patterning and oropharyngeal swallowing impairment in patients undergoing evaluation for lung transplant
Neurogastroenterology & Motility
2024 - Impact of bridging veno-venous extracorporeal membrane oxygenation to COVID-19 lung transplantation
Journal of Thoracic Disease
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Everett Vokes, MD
University of Chicago
Ralph Weichselbaum, MD
University of Chicago
Mary Rinella, MD
University of Chicago
Elliot Gershon, MD
University of Chicago
Justin Oldham, MD
University of Michigan
Fernando Martinez, MD
University of Massachusetts Chan Medical School
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”